NEW YORK (360Dx) – A multiplexed nanoplasmonic assay designed specifically to fit into clinical workflows is taking aim at high-throughput detection of pancreatic ductal adenocarcinoma (PDAC), an aggressive and often inoperable form of pancreatic cancer.

Developed by researchers at Harvard Medical School and Massachusetts General Hospital, the assay employs a liquid biopsy approach, leveraging low blood volumes and the clinical potential of exosomes — tiny vesicles shed by all kinds of cells, including tumor cells.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.